Skip to main content

and
  1. Article

    Open Access

    Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

    The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with pla...

    S S Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey in Blood Cancer Journal (2017)

  2. Article

    Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

    Correction to: Blood Cancer Journal (2016) 6, e453; doi:10.1038/bcj.2016.64 The purpose of this corrigendum is to publish grant support omitted in the manuscript 16-BCJ-0175T entitled, ‘Dose-dense and less dos...

    Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke in Blood Cancer Journal (2016)

  3. Article

    Open Access

    Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

    Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used and we reported that gene expression profile (GEP)-d...

    Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke in Blood Cancer Journal (2016)